Elevated Nocturnal CO 2 and Autonomic Dysfunction in Children With Down Syndrome
Jessica Taytard, Segolène Falquero, Sophie Denamur, Pierre‐Yves Boelle, Karl Leroux, Harriet Corvol, Aimé Ravel, Clotilde Mircher, Jeanne Toulas, Emmanuelle Prioux, Marie‐Anne Caillaud, Guillaume Aubertin, Hervé WaltiABSTRACT
Background
Sleep‐disordered breathing (SDB) frequently complicates Down syndrome (DS). Beyond upper airway obstruction, emerging evidence suggests an autonomic nervous system (ANS) dysfunction affecting CO 2 regulation. The aim of this study was to investigate nocturnal gas exchanges in children with DS and compare them to what has been observed in typically developing (TD) children, describe clinical signs of SDB and ANS dysfunction, executive functioning and motor skills and explore potential associations between PtcCO 2 levels and neuropsychological outcomes.
Methods
In this prospective study, children with DS aged 4–16 years without previously identified obstructive sleep apnoea were recruited between October 2019 and March 2022. Clinical assessment, autonomic symptom, executive function questionnaires and home overnight transcutaneous oxycapnography were performed; children with symptoms and/or elevated PtcCO 2 underwent polysomnography.
Results
Forty‐eight children with DS (median age: 8.0 [7.0–12.0] years) were included, of whom 30 had interpretable overnight SpO 2 and PtcCO 2 recordings. Median mean nocturnal PtcCO 2 was 44 [40–46] mmHg, significantly higher than in TD children ( p = 0.01), including in the subgroup with no or mild OSA (45 [41.5–46] mmHg). The most frequent clinical signs of SDB were restless sleep (62%), concentration difficulties (54%) and snoring (48%), whereas ophthalmic (51%) and digestive (46%) symptoms of autonomic dysfunction were common. No association was found between nocturnal PtcCO 2 and executive functioning or motor skills.
Conclusion
Children with DS exhibit higher nocturnal PtcCO 2 levels than TD children, along with clinical features suggestive of dysautonomia, supporting the hypothesis of a global ANS dysfunction affecting chemosensitivity.